University of Cincinnati

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, University of Cincinnati sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).

245 total trials 34 currently recruiting 172 completed top decile by trial count

University of Cincinnati: 245 sponsored US clinical trials, 34 recruiting.

University of Cincinnati sponsors 245 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 172 completed. 65 of these trials are in Phase 3-4 (later-stage) and 56 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stroke, with 9 trials.

Top-decile sponsor footprint

University of Cincinnati ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

172 of 189 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

245 total, page 4 of 5

TERMINATED Phase 1

Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients

NCT01477697

COMPLETED NA

Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model

NCT01477710

COMPLETED Phase 2

Letrozole for Lymphangioleiomyomatosis

NCT01353209

COMPLETED

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

NCT01335230

COMPLETED

Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Bronchoscopic Findings

NCT01904305

COMPLETED Phase 2

The Spot Sign for Predicting and Treating ICH Growth Study

NCT00810888

COMPLETED

Peroxisomal Defects and Familial Risk for Bipolar Disorder

NCT01237379

COMPLETED Phase 4

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

NCT01336296

COMPLETED

Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)

NCT01202864

COMPLETED

Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage

NCT01406457

COMPLETED

Radiation Planning Study for High Grade Brain Tumors

NCT01191346

TERMINATED Phase 3

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

NCT01111682

COMPLETED

Effects of Transport on Patients With Traumatic Brain Injury

NCT01077089

COMPLETED

Challenging the Gold Standard: Pilot Study Comparing Continuous Glucose Monitoring System (CGMS), Capillary Glucose Monitors and 3 Hour Glucose Tolerance Test (GTT) to Diagnose Gestational Diabetes Mellitus (GDM)

NCT01074489

COMPLETED Phase 3

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT01077024

COMPLETED

Pre-hospital Hypoxemia in Trauma Patients

NCT01074983

COMPLETED NA

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

NCT01746303

TERMINATED

Measurements to Assess Severity of Epicardial Stenoses

NCT00760630

COMPLETED NA

Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer

NCT00981812

COMPLETED Phase 2

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803

COMPLETED Phase 2

Rituximab for Pulmonary Sarcoidosis

NCT00855205

COMPLETED

Study to Measure the Prevalence of Asynchrony In Mechanically Ventilated Patients

NCT01049958

COMPLETED Phase 2

Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania

NCT00917501

COMPLETED Phase 4

Desensitization in Kidney Transplantation

NCT00908583

COMPLETED NA

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581

COMPLETED

Observational Study of Cortical Spreading Depression in Human Brain Trauma

NCT00803036

COMPLETED Phase 1

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

NCT00885495

COMPLETED Phase 4

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507

COMPLETED Phase 2

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274

COMPLETED NA

Energy Metabolism and Cognitive Aging

NCT00777010

COMPLETED Phase 4

Quetiapine in Melancholic Depression

NCT01200901

COMPLETED Phase 2

Randomized Trial for Mixed Acute Rejection

NCT00771875

COMPLETED Phase 4

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

NCT00782821

COMPLETED Phase 4

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

NCT00771745

COMPLETED NA

Standardized Criteria to Judge Diagnostic Urethrocystoscopy Skills

NCT00631761

COMPLETED Phase 2

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

NCT00581607

COMPLETED Phase 4

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

NCT00550394

COMPLETED

Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis

NCT00875940

COMPLETED

An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.

NCT00628927

COMPLETED NA

Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure

NCT00585832

COMPLETED

Functional and Neurochemical Brain Changes Bipolar Depression

NCT00608296

COMPLETED Phase 1

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)

NCT00603434

COMPLETED Phase 2

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

NCT00585390

COMPLETED

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

NCT00609193

COMPLETED Phase 4

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

NCT00526630

COMPLETED Phase 2

Use of Armodafinil for Fatigue in Sarcoidosis

NCT00555347

COMPLETED Phase 4

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436

COMPLETED Phase 2

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810

TERMINATED Phase 2

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

NCT00585585

TERMINATED Phase 4

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

NCT00477802

← Previous Page 4 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 33
Phase 3 19
Phase 4 46

What is open in the University of Cincinnati pipeline

34 recruiting of 245 indexed (14% open); 172 completed (70%).

Phase mix: 65 late (III/IV) vs 56 early (I/II) (balanced across stages).

Top condition: Stroke (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Cincinnati: open-pipeline peers nationwide

Peers matched on 245 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

University of Cincinnati sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%5%10%15%20%25% Total trials Recruiting share University of CincinnatiShireState University of New York at BuffaloMasonic Cancer Center, University of MinnesotaUniversity of Massachusetts, WorcesterMilton S. Hershey Medical CenterJohns Hopkins Bloomberg School of Public HealthBeiGeneSeattle Institute for Biomedical and Clinical Research
University of Cincinnati sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Cincinnati sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 245 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this University of Cincinnati page

245 registered trials is a research-attention snapshot, not an endorsement of University of Cincinnati or any single study.

  • 34 of University of Cincinnati's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Stroke is the condition University of Cincinnati studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stroke trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Cincinnati pipeline card: 245 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.